Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Collaborations Pharmaceuticals

1 Drug Candidate

Collaborations Pharmaceuticals is a Raleigh, North Carolina-based drug discovery company using generative AI to design novel psychoplastogens for substance use disorders. Its lead candidate DM506 is a non-hallucinogenic, non-cardiotoxic synthetic ibogamine derivative (ibogaminalog) that has shown preclinical efficacy in reducing cue-induced heroin-seeking and modulating prefrontal cortex GABA currents in opioid use disorder models.

Drug Pipeline

1

DM506

Pre-clinical
Opioid Use Disorder (OUD)

Ibogaminalog (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole fumarate). Non-hallucinogenic, non-cardiotoxic synthetic ibogamine analog. Single dose reduces cue-induced heroin-seeking in preclinical OUD models; also shows antidepressant-like activity via serotonergic pathways.

Quick Facts

Type
Private Biotech
Lead Stage
Pre-clinical
Website
Visit